By 2030, it is anticipated that the Brazil liver cancer therapeutics market will reach a value of $286.7 Mn from $73.25 Mn in 2022, growing at a CAGR of 18.6% during 2022-30. The liver cancer therapeutics market in Brazil is dominated by a few domestic pharmaceutical companies such as Eurofarma, Aché Laboratórios, and Libbs Farmacêutica. The liver cancer therapeutics market in Brazil is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
By 2030, it is anticipated that the Brazil liver cancer therapeutics market will reach a value of $286.7 Mn from $73.25 Mn in 2022, growing at a CAGR of 18.6% during 2022-2030.
Brazil is an upper middle-income, developing and the largest country in South America bounded by the Atlantic Ocean. According to the latest WHO data published in 2020 Liver Cancer Deaths in Brazil reached 11,514 or 1.02% of total deaths. The age-adjusted Death Rate is 4.81 per 100,000 of the population ranks Brazil 105th in the world. In Brazil, liver cancer is responsible for 11% of all gastrointestinal malignancies, with alcohol consumption being a contributing factor.
Other treatments utilized in Brazil for HCC, in addition to targeted medicines and chemotherapy, include surgery, radiation therapy, and transarterial chemoembolization (TACE), a method that delivers chemotherapy chemicals directly to the tumor via the hepatic artery. Brazil's government spent 10.3 % of its GDP on healthcare in 2020.
Market Growth Drivers
In recent years, the incidence of liver cancer in Brazil has progressively increased, owing primarily to the high frequency of hepatitis B and C infections, alcohol consumption, and non-alcoholic fatty liver disease. In recent years, several innovative medicines for liver cancer, including targeted therapies and immunotherapies, have been licensed in Brazil. These novel therapies provide patients with better treatment alternatives and are projected to boost market expansion.
Market Restraints
The Brazilian healthcare system is fragmented, with public and private providers coexisting. This can make it difficult for patients and clinicians to access and deliver liver cancer therapies. Brazil's competitiveness is hampered by high manufacturing costs (wages, energy, logistics, and loans).
Key Players
September 2022: Sirtex Medical of Australia has received favorable approval in Brazil for SIR-Spheres Y-90 resin microspheres for HCC treatment. ANS supports SIR-Spheres for use in selective internal radiation therapy (SIRT), a minimally invasive treatment that delivers high doses of radiation specifically to malignancies while sparing surrounding healthy liver tissue, in an update to its List of Health Procedures and Events. SIR-Spheres got product approval from the Brazilian Health Regulatory Agency (ANVISA) in 2014.
September 2022: Aché Laboratories has started a new approach to prospecting and creating novel pharmaceuticals based on Brazilian biodiversity. The company maintained its cooperation with the innovation consultant Emerge Brasil for the second year in a row, with the goal of improving its understanding of the seven Brazilian biomes and creating new sustainable business prospects.
In Brazil, the regulatory body responsible for approving liver cancer therapeutics is the National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA). The reimbursement of liver cancer therapeutics in Brazil is largely determined by the Brazilian Unified Health System (Sistema Único de Saúde, SUS).
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Type (Revenue, USD Billion):
By Treatment (Revenue, USD Billion):
By Equipment (Revenue, USD Billion):
By Route of Administration (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.